2017 Insulin Delivery Devices Market by Type (Insulin Pens (Reusable, Disposable), Insulin Pumps (External/Tethered, Patch), Pen Needles (Standard, Safety), Insulin Syringes) - Global Forecast to 2021 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Insulin Delivery Devices Market by Type (Insulin Pens (Reusable, Disposable), Insulin Pumps (External/Tethered, Patch), Pen Needles (Standard, Safety), Insulin Syringes) and End User (Patients/Homecare, Hospitals & Clinics) - Global Forecast to 2021" report to their offering.

The insulin delivery devices market is projected to reach USD 17.85 billion by 2021 from USD 11.54 billion in 2016, growing at a CAGR of 9.1% in the next five years (2016 to 2021).

Favorable reimbursement scenario and strong government support in selected countries, technological advancements in insulin delivery devices, growing diabetic population, and rising awareness about insulin delivery devices are the major factors driving the growth of this market. However, needle anxiety, emergence of oral drug delivery methods, and the growing trend of reuse of pen needles and infusion sets are the major factors restraining the growth of this market.

Furthermore, increasing research and development activities and increasing diabetes-related health expenditure in emerging countries are likely to offer significant growth opportunities for players operating in the market.

Market Dynamics

Drivers

  • Growing Diabetic Population
  • Technological Advancements in Insulin Delivery Devices
  • Favorable Reimbursement Environment and Government Support in Selected Countries
  • Conferences, Meetings, and Congresses to Create Awareness About Insulin Delivery Devices

Restraints

  • Poor Reimbursement Structure in Developing Countries
  • Needle Anxiety in Patients to Affect the Growth of the Pen Needles and Syringes Market
  • Oral Insulin as an Alternative Drug Delivery Method
  • Issues Associated With the Reuse of Pen Needles and Infusion Sets

Opportunities

  • Increasing Research and Development Activities
  • Increasing Diabetes-Related Health Expenditure in Emerging Economies
  • Safety Needles

Challenge

  • Severe Shortage of Endocrinologists in the U.S.

Companies Mentioned

  • Animas Corporation (Johnson and Johnson)
  • Becton, Dickinson and Company
  • Biocon Limited
  • ELI Lilly and Company
  • Insulet Corporation
  • Medtronic PLC
  • Novo Nordisk A/S
  • Sanofi
  • Tandem Diabetes Care, Inc.
  • Ypsomed Holding AG

For more information about this report visit http://www.researchandmarkets.com/research/bfp2pf/insulin_delivery

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Diabetes Devices

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Diabetes Devices